BriaCell Therapeutics Corp. announces that certain members of its Management team have informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% of the Company’s basic common shares outstanding.

Mizuho analyst Mara Goldstein's top oncology stock picks for 2022 include Arcus Biosciences (RCUS), Autolus Therapeutics (AUTL), Fate Therapeutics (FATE) and Leap Therapeutics (LPTX). This is based on the analyst's expectation of "meaningful data catalysts" from these companies.

Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update LPTX BGNE

Ocular Therapeutix files $300M mixed securities shelf Read more at: thefly.com/n.php?id=38108…